AbbVie Inc (ABBV)vsAMN Healthcare Services Inc (AMN)
ABBV
AbbVie Inc
$263.65
+0.04%
HEALTHCARE · Cap: $447.53B
AMN
AMN Healthcare Services Inc
$34.70
+0.03%
HEALTHCARE · Cap: $1.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1737% more annual revenue ($62.82B vs $3.42B). ABBV leads profitability with a 5.8% profit margin vs -0.9%. ABBV appears more attractively valued with a PEG of 0.42. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AMN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$263.65
$116.39 premium
Margin of Safety
+59.9%
Fair Value
$48.75
Current Price
$34.70
$14.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Revenue surging 99.9% year-over-year
Earnings expanding 321.3% YoY
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Expensive relative to growth rate
Smaller company, higher risk/reward
Elevated debt levels
ROE of -4.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : AMN
The strongest argument for AMN centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 99.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : AMN
The primary concerns for AMN are PEG Ratio, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while AMN is a hypergrowth play — different risk/reward profiles.
AMN carries more volatility with a beta of 0.41 — expect wider price swings.
AMN is growing revenue faster at 99.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 62/100) and 12.4% revenue growth. AMN offers better value entry with a 59.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
AMN Healthcare Services Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
AMN Healthcare Services, Inc. provides healthcare personnel solutions and staffing services to hospitals and healthcare facilities in the United States. The company is headquartered in Dallas, Taxas.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?